Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

April 28, 2023

https://www.globenewswire.com/news-release/2023/04/28/2657401/0/en/Processa-Pharmaceuticals-to-Present-PCS12852-Gastroparesis-Results-at-the-Digestive-Disease-Week-2023-Annual-Meeting.html

HANOVER, MD, April 28, 2023 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, today announces it will be presenting data on the use of PCS12852 to treat gastroparesis patients at the annual Digestive Disease Week (DDW) conference held in Chicago’s McCormick Place from May 6-9, 2023. PCS12852 is a Phase 2b-ready, very potent and very selective novel 5-HT4 agonist, for which the company is exploring partnerships and other options to advance the program.

Read more at globenewswire.com

Related news for (PCSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.